research investigating the effect of folic acid supplementation on arterial stiffness showed conflicting results, [6] [7] [8] [9] [10] and some trials have found folic acid supplementation have no effect on PWV in European patients. [8] [9] [10] Uncertainty remains regarding the efficacy of folic acid supplementation on arterial stiffness in hypertension patients in China with lower baseline folate levels and higher homocysteine levels. Methylenetetrahydrofolate reductase (MTHFR) is the regulatory enzyme for folic acid metabolism, and it is recognized that folic acid supplementation could have individual effect in different MTHFR genotype. This subgroup analysis of CSPPT investigates efficacy of folic acid supplementation on arterial stiffness in hypertension patients in China, as well as assesses the modifying effect of the MTHFR gene on the association between folic acid supplementation and PWV.
| MATERIAL S AND ME THODS

| Study population
The study population was from the CSPPT trial (clinicaltrials.gov identifier: NCT00794885). The CSPPT was multicenter, randomized, double-blind trial conducted from 2008 to 2013. The study enrolled 20 702 adults with hypertension and without stroke, heart failure, or myocardial infarction. 4 Hypertension patients were randomized to receive either combination of enalapril and folic acid or enalapril alone, and participants were followed up for 5 years. Other type of antihypertensive medications could be prescribed to improve blood pressure control. Briefly, we enrolled 2529 CSPPT participants who were monitored the change of PWV, recorded the main adverse F I G U R E 1 Flowchart of the study. CSPPT, China Stroke Primary Prevention Trial TA B L E 1 Baseline and follow-up characteristics of participants between quartile groups of folic acid supplementation The inclusion criteria for the our study are described as below 4 :
(a) aged 45-75 years and (b) patients with hypertension, defined as resting systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. The major exclusion criteria included stroke, heart failure, myocardial infarction, and coronary heart disease. Informed consent was obtained from all subjects.
| Laboratory assays
All participants underwent interviews, which were carried out by cardiologist. Blood samples were collected separated within 20 minutes and were stored at −70°C. Hcy (homocysteine) was measured by high-performance liquid chromatography described by Araki and Sako. waveforms (ΔTba, in seconds). 13 We used the higher of the bilateral ba-PWV measurements in our analysis for comparison to other studies.
| Follow-up
Participants were scheduled for follow-up for 5 years. At each follow-up, blood pressure, physical signs, concomitant medication use, main cardiovascular events, and possible end-point events were documented by trained researcher and physicians. Doctor will adjust the anti-hypertension drug according to the situation of blood pressure to make the patients' blood pressure within 140/90 mm Hg in follow-up. During the trial period, use of other antihypertensive drugs was allowed.
| Statistical analysis
Continuous data are presented as mean ± standard deviation (SD), while categorical variables are expressed as median (interquartile range Differences in population characteristics were compared using ANOVA or chi-square tests.
Change=exit data minus baseline data. DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure.
TA B L E 1 (Continued) statistical analyses were performed using SPSS statistical software (version 18.0; SPSS, Inc., Chicago, IL, USA).
| RE SULTS
Flow diagram of the trial is demonstrated in Figure 1 . In total 2529 participants, the mean age of the study population was 59.6 ± 7.3 years, and 42.1% were male. The median homocysteine level was 14.5 mmol/L. Study patients were classified into quartiles according to folic acid status after supplementation (exit folic acid levels minus baseline folic acid levels): Q1: (<3.19), Q2: (3.19-7.14), Q3: (7.14-12.51), and Q4: (>12.51). Clinical characteristics of the study population as a whole and by quartiles are showed in Table 1 .
There were no significant differences in the baseline blood pressure and baseline PWV over quartiles according to folic acid supplementation. Exit homocysteine levels were 3.5 mmol/L lower in the highest quartile of folic acid supplementation than in the lowest quartile. Decrease of homocysteine was also significantly greater in the highest folic acid supplementation than in the lowest (−3.1 ± 8.2
vs 0.7 ± 6.8, P < 0.001). SBP and DBP showed no significant differences over quartiles according to change in folic acid during the fol- Differences in population characteristics were compared using ANOVA or chi-square tests. Change=exit data minus baseline data. DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure.
with CC genotype and had no significant difference in baseline PWV compared with CC genotype (Table 2 ).
In multiple logistic regression models, we found that folic acid supplementation (as a continuous variable) was significantly correlated with change in ba-PWV for the entire study population after adjustment for age, gender, blood pressure and the other cardiovascular risk factors (β = −1.31, P < 0.001, Table 3 ). Hypertension patients with the CC genotype had significantly greater PWV response to folic acid supplementation than did carriers of the T allele (β = −2.79, P < 0.001 for CC homozygotes compared with β = −0.56, P = 0.464 for TT homozygotes). We did not found significant association of folic acid supplementation and improvement of PWV in hypertension TA B L E 3 Multiple linear regression models examining the impact of folic acid supplementation (as a continuous variable and by quartiles) on change in pulse wave velocity in different MTHFR genotype strata Model 1: Adjusted for age, gender, serum folate, baseline systolic blood pressure, baseline diastolic blood pressure, and baseline PWV (pulse wave velocity); Model 2: Adjusted for study center, smoking status, BMI, baseline homocysteine, total cholesterol, and fasting glucose, in addition to covariates in Model 1; Model 3. Adjusted for age, gender, center, treatment group, body mass index, heart rate, smoking, alcohol intake, baseline serum total cholesterol, serum HDL cholesterol, triglycerides, uric acid, homocysteine, folate, serum creatinine, fasting glucose, type of antihypertensive drugs, baseline systolic blood pressure, baseline diastolic blood pressure, follow-up mean systolic blood pressure, follow-up mean diastolic blood pressure, and baseline PWV (pulse wave velocity).
patients with TT genotype, whereas in the CC genotype, we found a clear correlation between folic acid intake and improvement of PWV (P for interactions = 0.034).
A subgroup analysis showed folic acid supplementation improve PWV in those patients with normal weight (BMI <25 kg/ m 2 ) and in elder patients (age > 60 year). There was no statistically significant interaction effect in the subgroup analysis on the impact of folic acid supplementation on PWV. The modifying effect of the MTHFR genotype and folic acid on improving PWV remained significant in the subgroup analysis, as shown in Table 4 and Figure 2 .
| D ISCUSS I ON
Pulse wave velocity is measured to access arterial stiffness and is recognized as a strong predictor of MACEs. [14] [15] [16] [17] Within this multicenter randomized controlled cohort trial (CSPPT study), we Adjusted for age, gender, center, treatment group, body mass index, heart rate, smoking, alcohol intake, baseline serum total cholesterol, serum HDL cholesterol, triglycerides, uric acid, homocysteine, folate, serum creatinine, fasting glucose, type of antihypertensive drugs, baseline systolic blood pressure, baseline diastolic blood pressure, follow-up mean systolic blood pressure, follow-up mean diastolic blood pressure, and baseline PWV (pulse wave velocity).
observed change in folate was positively correlated with change in ba-PWV for the study population after adjustment for age, gender, blood pressure, and the other cardiovascular risk factors, and folic acid supplementation did lead to a reduction in PWV.
These findings are consistent with the hypothesis that folic acid supplementation reduces large artery stiffness. 7 Furthermore, the effect of folic acid supplementation was modified by MTHFR gene C677T polymorphism. The artery stiffness improvement by folic acid supplementation in CC genotype was more significant.
We also observed positive effect of folic acid treatment on Hcy levels, since Hcy level has direct effect on the cardiac disease, 18 and folic acid supplementation is assumed to reduce the risk of cardiovascular disease. A few other trials have investigated the effect of folic acid supplementation on arterial stiffness or carotid intima-media thickness [6] [7] [8] [9] [10] [19] [20] [21] [22] ; however, the results of these studies were conflicting. We identified some factors implicated the effect of folic acid therapies in these studies. Firstly, our study patients are hypertensive patients in the rural areas of China with high level of Hcy. Secondly, our trial observed folic acid supplement for 5 years, and shortterm follow-up is not easy to get positive results, and longer follow-up is necessary. 23 Lastly, most previous trials were performed in lower cardiovascular risk patients with higher baseline folate levels, and we found that the beneficial reducing PWV effect appeared to be more pronounced in subjects with lower baseline folate levels. The baseline folate levels in the B-PROOF trial were 19 nmol/L, 10 and some previous folic acid supplement trials conducted in high baseline folic acid areas, so they tend to get null results of folic acid supplementation. 24 Polymorphisms of MTHFR gene C677T lead to decrease of folate levels and increase of homocysteine level. In previous studies, folic acid therapy significantly reduced stroke events in participants with the CC genotype, and the preventive effect of folic acid therapy on stroke was closely related to the amount of folic acid supplementation. 4 A large meta-analysis and some trials showed the effect of the MTHFR C677T gene on stroke and MACE risk might be modified by baseline folate status. 25 We have found modifying 
| CON CLUS ION
In a subgroup of Chinese hypertensive patients who had received 5-year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation.
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